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Abstract
Background and Objective: Synergistic combinations of various antimicrobial agents have been introduced as extra successful strategies
to combat multidrug resistant (MDR) infections. This study was undertaken to evaluate MDR profiling of Staphylococcus aureus  strains
isolated  from  clinical  specimens  of  two  public  hospitals  of  twin  Pakistani  cities  as  well  as  to  explore   in   vitro   antibacterial
potential of Nigella  sativa  L. (black  cumin  or  black  seeds)  extract  against  Mec  A  gene  positive  Staphylococcus  aureus  strains.
Materials and Methods: The MDR strains were then screened for positive Mec A gene by PCR and sequencing. A total of 500 bacterial
strains were subjected to antimicrobial and Nigella sativa  seeds susceptibility and minimal inhibitory concentration assays. The data were
evaluated as Mean±Standard deviation of five independent experiments. The results were analyzed using t-test with SPSS version 16.0.
Results: Methanolic extracts of Nigella sativa  seeds showed maximum activity against Mec A gene positive Staphylococcus aureus  alone
and in combination with the penicillin antibiotic Augmentin® plus the second-generation Cephamycin, Cephalosporins, Mefoxin®
(Cefoxitin). The anti-MRSA activity was reduced when methanolic extracts of Nigella sativa  seeds were used in combination with the pain
reliever and the fever reducer paracetamol (acetaminophen). Eventually, it has been observed that the anti-staphylococcal activity of
Nigella sativa  led to changes in bacterial cell morphology indicating that the cell wall of Gram-positive bacteria as likely a target of action.
Conclusion: This study provides new insights about synergistic antimicrobial and Nigella sativa crude extract activities against MDR
Staphylococcus aureus  strains.
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INTRODUCTION
The  third  significant  cause  of  mortality  around  the
world is infectious diseases as estimated by World Health
Organization1. Methicillin-Resistant Staphylococcus aureus
(MRSA) infections have become a global health problem
particularly in hospital setup causing simple skin infections to
life-threatening infections2,3. In many developing countries,
including Pakistan, the situation appears depressing due to
inadequate implementation of policy on infection control, lack
of political will, too little resources, poor motivation of health
care   workers   and   researchers4-6.   Staphylococcus   aureus
(S. aureus) is a Gram positive bacterium and is known to
develop   quick   resistance   to   antimicrobial   agents.
Staphylococcus aureus usually cause community acquired
post-operative infections, endocarditis, toxic shock syndrome,
food poisoning and osteomyelitis7-9.
Genetic mutation was involved in the development of
resistance of antibiotic. The attainment of Mec A gene by
horizontal transmission by conjugation was the main cause of
antibiotic resistance in S. aureus10. In bacterial genome mobile
hereditary component called Staphylococcal chromosome
cassette (SCCmec) carried Mec A gene11,12. The altered
penicillin binding protein abbreviated as PBP2a is coded by
Mec A gene that has a low affinity for antibiotics belongs to
beta lactam, the active site of altered PBP2a cannot bind to
methicillin or other $-lactam antibiotics13,14.
The increasing incidence of drug-resistant pathogens has
drawn the attention of the pharmaceutical and scientific
communities towards studies on the potential antimicrobial
activity  of  plant-derived  substances,  which  are  used  in
traditional medicine in different countries15-17. The use of and
search for drugs derived from plants have accelerated in
recent years. Ethnopharmacologists, botanists, microbiologists
and natural-products chemists are working in collaboration to
find new plant based antibiotics for treatment of infectious
diseases18,19. Plants are rich in a wide variety of secondary
metabolites, such as tannins, terpenoids, alkaloids and
flavonoids, which have been found in vitro to have
antimicrobial properties20,21. Scientists from divergent fields
are investigating plants with an eye to their antimicrobial
usefulness. A sense of urgency accompanies the search as the
pace of species extinction continues22. Laboratories of the
world  have  found  literally  thousands  of  phytochemicals
which have inhibitory effects on all types of microorganisms
in vitro19. More of these compounds should be subjected to
animal  and  human  studies  to  establish  their  efficacy  in
whole-organism  systems,  including  in  particular  toxicity
studies   as   well   as   an   examination   of   their   effects   on
advantageous normal microbiota. It would be useful to
standardize methods of extraction and in vitro  testing so that
the search could be more systematic and interpretation of
results would be facilitated23.
Nigella sativa (N. sativa) (Family Ranunculaceae) is a
broadly used medicinal plant throughout the world. It is very
popular in a variety of traditional systems of medicine like
Unani and Tibb, Ayurveda and Siddha. Seeds and oil have a
long history of folklore usage in various systems of medicines
and food. The seeds of N. sativa  have been broadly used in
the treatment of different diseases and ailments24. In Islamic
literature, it is well thought-out as one of the best forms of
healing medicine. It has been suggested for using on regular
basis in Tibb-e-Nabwi (Prophetic medicine). It has been widely
used  as  antihypertensive,  liver  tonics,  diuretics,  digestive,
anti-diarrheal, appetite stimulant, analgesics, anti-bacterial
and in skin disorders. Due to its miraculous power of healing,
N. sativa has got the place among the top ranked evidence
based herbal medicines. It has a potent bioactive known as
thymoquinone which shows promise in treating epilepsy,
allergies   and   boosting   the   immune   system25.   The
ethnobotanical studies showed it is a medicinal plant essential
in the treatment of microbial infections26. Bakathir and Abbas
indicated that the aqueous extract of N. sativa had a
significant antibacterial activity27. However, as a further study
in cognizance of challenges of multidrug resistant bacteria, its
antibacterial effect in combination with different first-line
antibiotics commonly used against infectious agents needs to
be investigated. The synergistic antimicrobial effects of crude
methanolic extract in combination with $-lactam antibiotics
will advance new knowledge because it has not yet done.
The aim of this study was to screen the antibacterial
activity  of  N.  sativa  (black  seeds),  which  is  commonly  used
in  the  Pakistani  population.  Aqueous  and  methanolic
preparations of plant extracts were tested for antibacterial
activity against a S. aureus  strains isolated from diverse clinical
specimens. In vitro synergistic potential of N. sativa seeds
extract  with  second  generation  cephalosporins  and
augmentin, a $-lactamase inhibitor was determined. Their
effects on bacterial morphology were also determined.
MATERIALS AND METHODS
Reagents: All solvents (ethanol, ethyl acetate, methanol,
dimethylsulfoxide (DMSO) were purchased from Merck,
Germany.  Nutrient  media:  Mueller-Hinton  broth  and
Mueller-Hinton agar were purchased from Oxoid, Hamshire,
UK. Standard discs of antibiotics (amoxicillin, chloramphenicol,
streptomycin, tetracycline, rifamycine) were from Oxoid,
Hamshire, UK.
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Plant  material:  Nigella  sativa  (seeds)  were  obtained
commercially    from    the    market.    Dried,    ground    seeds
(50 g for each extract) were extracted with water, ethanol,
methanol and ethyl acetate by maceration. After being
concentrated, stock solutions of extracts (80 mg mLG1) were
obtained by dissolving a certain amount of crude extract in
solvent (5% DMSO). The yields of the extracts were 11.6 g for
water extract, 5 g for ethanol extract and 5.3 g for ethyl
acetate extract and 15 g for methanol.
Isolation of S. aureus from clinical specimens: Total 500
different strains of S. aureus were collected from Pakistan
Institute of Medical Sciences hospital Islamabad and Holy
Family hospital Rawalpindi, Pakistan over a period of one year
(Dec., 2014-Jan., 2016). Samples collected were of different
nature such as blood, pus, wounds, trachea and ear discharge.
Blood agar and Mueller Hinton agar media were used to
inoculate the samples. Staphylococcus aureus  was identified
on the basis of colonial, cellular morphology and biochemical
test like catalase test, coagulase test, DNase test. Identification
was also confirmed by 16S rRNA gene sequencing by using
GAGTTTGATCCTGGCTCAG and AGAAAGGAGGTATCCAGCC
forward and reverse primer sequence, respectively.
Inoculum preparation: Bacterial suspension was prepared
from overnight cultures by the direct colony method. Colonies
were taken directly from the plate and suspended into 5 mL of
sterile 0.85% saline. The turbidity of initial suspension was
adjusted comparing with 0.5 McFarland standard. When
adjusted to the turbidity of a 0.5 McFarland standard, a
suspension of bacteria contains about 108 Colony Forming
Units  (CFU)  mLG1.  Ten-fold  dilutions  of  initial  suspension
were  additionally  prepared  into  sterile  0.85%  saline  to
achieve 106 CFU mLG1.
Antibiotic  sensitivity  profiling:  Antibiotic  susceptibility
testing  was  done  for  S.  aureus  strains  under  the  standard
CLSI guidelines28. Staphylococcus aureus  was cultured on
Mueller-Hinton   agar.   Different   antibiotic   drugs
(chloramphenicol, gentamicin, clindamycin, ceftoxitin,
sulfamethoxazole) discs were used to check their sensitivity.
Antibiotic discs were placed on the surface of a Mueller-Hinton
agar that has been inoculated with S. aureus. After  18-24  h 
the diameter of zone of inhibition were measured according
to reference tables29.
Molecular characterization of S. aureus: The MRSA isolates
were subjected to 16S rRNA sequencing.  The PCR was done
on following  conditions;  94EC  for  4  min  followed  by  94EC 
for 1 min then 57EC for 1 min and 72EC for 1 min and at the
end 72EC for 7 min. Reaction volume was 30 µL with (16S)
forward   (GAGTTTGATCCTGGCTCAG)   and   reverse
(AGAAAGGAGGTATCCAGCC) primer sequence.
Detection of Mec A gene by PCR and sequencing of Mec A
gene:  Out  of  500  isolated  S.  aureus  strains  from  diverse
clinical specimen 278 strains showed resistance to more than
one antibiotic. Multiple antibiotic resistant strains were
selected for screening Mec A gene positive strains. Cells were
suspended in a lysis buffer containing 1 M tris HCl, 5 M NaCl
and 0.1 M EDTA, which was incubated at 95EC for 10 min. After
incubation, the suspension was centrifuged at 23 000×g for
5 min. The supernatant was used as a template in PCR. Three
step PCR method was carried out using XP thermal cycler29.
Published  primer  Mec  A  were  used  for  amplification30,31.
The      final      PCR      products      were      visualized      using
UV-transilluminator  after  electrophoresis  on  1.5%  agarose
gel containing 50 mg mLG1 EtBr.
Primer for Mec A gene: For amplification of 163 bp region
forward primer sequence (CTGGTGAAGTTGTAATCTGG) and
reverse primer sequence (ACTGCTATCCACCCTCAAAC) were
used.
DNA sequencing on ABI3130 genetic analyzer: After
electrophoresis the amplified PCR product was purified to be
further used for sequencing reaction. For sequencing reaction
4 µL of big dye, 5 µL purified PCR product, reverse and forward
primers 1 µL were added  to  make  total  reaction  volume  of
10 µL. Sequencing conditions were 96EC for 1 min for one
cycle, then 96EC for 15 sec and 55EC for 4 min for 25 cycles.
Product  of  sequencing  reaction  was  purified.  Sequencing
was run using ABI 3130 genetic analyzer and results were
analyzed.
Antimicrobial activity of crude extract of seeds of N. sativa:
A total of 500 bacterial strains were subjected to antimicrobial
susceptibility and MIC assays. In addition, reference strains
such as S. aureus  ATCC 25923, was run each time as control
for susceptibility and MIC assays. Plant extracts were screened
for antimicrobial activity using the agar well diffusion method.
Bacterial cultures were inoculated in LB broth for 3 h at 37EC
and turbidity was adjusted in Phosphate Buffered Saline (PBS)
to 0.5 McFarland’s index. Using a sterile cotton swab, a
bacterial lawn was spread on 90 mm MHA plates containing
6 mm wells. Twenty microliters of plant extracts were poured
into each well and plates were incubated at 37EC aerobically
for 18 h. Plates were incubated in microaerophilic conditions
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using a Campygen kit (Oxoid, Hamshire, UK) at 37EC for 48 h.
The diameter of the zone of bacterial inhibition around each
well was measured32.
Determination   of   MIC   and   MBC:   Minimum   Inhibitory
Concentrations   (MICs)   and   Minimum   Bactericidal
Concentration (MBC) were determined by agar dilution and
micro broth dilution assays using MH agar and MH broth,
respectively33. The concentrations of the extracts tested
ranged from 5000-50 µg mLG1. In the case of agar dilution,
experiments were performed on MH agar plates containing
various concentrations of extracts (1:20 v/v). Plates were
inoculated with 10 µL of the test organism containing 105 CFU
log phase bacteria per spot and a total of 20 spots were tested
on one plate. In the case of the micro broth dilution assay,
sterile flat-bottom 96-well plates were loaded with 100 µL of
two-fold dilutions of extracts into each well. The starting
bacterial inoculums were 1.5×105 CFU mLG1. Plates without
any plant extracts were served as growth control. The assay
plates were incubated as described in this study. The highest
dilution of extract that showed no visible bacterial growth per
spot and no turbidity in agar dilution and micro broth dilution
assay respectively was considered as MIC.
To determine Minimum Bactericidal Concentration (MBC)
of extracts, 100 µL of MH broth from each well of micro broth
assay was sub-cultured on MH agar plates after 24 h of initial
incubation. The MH plates were incubated for another 24 h.
The lowest concentration of extract that resulted in no
bacterial growth was considered as MBC. Experiments were
performed in quadruplicate on five different occasions.
Synergistic   antimicrobial   assays:   Synergistic   activity   of
N. sativa  extract with second!generation cephalosporins and
augmentin  against  Mec  A  gene  positive  human  strains  of
S.  aureus  was  determined.  Nigella  sativa  seeds  methanolic
and aqueous extracts were tested against representative
strains of S. aureus ATCC 25923 and isolated clinical strains.
Each combination was first tested by the checkerboard
titration method using MH broth in microtiter plates as
described previously and by disk diffusion method34.
Concentrations  of  extracts  ranged  from  5000-5  µg  mLG1.
The antimicrobial activity of the extract and antibiotic
combination  was  interpreted  as  one  of  the  following
categories:  Synergy,  additive  effect  or  antagonism.  The
Fractional   Inhibitory   Concentration   (FIC)   of   each   agent
was  calculated  as  the  MIC  of  the  agent  in  combination,
divided by the MIC of the agent alone. The interpretation was
made on the basis of the fractional inhibitory concentration
index  (EFIC),  which  is  the  sum  of  the  FICs  of  both  agents.
The  FICI  results  were  interpreted  as  follows:  <0.5  synergy,
0.5-1 additive effect, 1-2 indifferent or no effect and >2
antagonism35.
Time kill kinetic assay: Time kill kinetic assays were
performed on successful synergistic combinations obtained by
checkerboard titration methods and disc diffusion assay.
Flasks containing 100 mL MH broth and the drug-plant extract
combination were inoculated with a log phase culture of the
test organism to a density of 1×105 CFU mLG1. Test strains
included S. aureus. Individual components of each
combination, either extract or antibiotic, were added to the
control flask to compare the effects of the synergistic
combinations to their individual effects on the bacterial
growth curve, while no drug was added to the growth control
flask. Flasks were incubated for 24 h at 37EC. Aliquots (100 µL)
were collected at different time intervals from each flask,
serially diluted in PBS and cultured on MHA plates to obtain
colony counts35,36. Curves were constructed by plotting the
log10  of  CFU  mLG1  versus  time.  Synergy  was   defined   as
>2 log10 decreases in CFU of organisms treated with the drug
combination compared to the most active component of the
alone as described previously37.
Phase contrast microscopy: On the basis of biological activity,
bacterial strains treated with sub-inhibitory concentrations
(0.5×MIC)  of  N.  sativa  seeds  methanolic  extract  was
subjected to phase contrast microscopy to see their effects on
bacterial   cell   morphology.   Exponential   phase   cultures
(A600,  0.05)  of  S.  aureus  grown  in  Luria  broth  were  treated
with Minimal Inhibitory Concentration (MIC) and sub lethal
concentration (1/2 MIC) of N. sativa  methanolic extract. Slides
were immediately made after treatment in 1% agarose using
4   µL   of   antibacterial   compound   (methanolic   extract   of
N. sativa) treated cultures, time lapse images were obtained
under phase contrast by OMAX 40X-2500X Phase Contrast LED
Trinocular Compound Microscope, USA. Particular care was
taken to minimize the sample exposure to UV light. Image
grabbing  were  performed  essentially  as  described  by
Edwards and Errington38.
Statistical analysis: It is a retrospective study, therefore, both
descriptive and influential statistical analysis was considered.
The  data  were  evaluated  as  Mean±Standard  deviation  of
five independent experiments. The results were analyzed
using t-test with SPSS version 16.0. The p<0.001 were
considered significant.
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RESULTS
Antimicrobial resistance profiling of isolated S. aureus
strains:  The  antibiotic  resistance  pattern  of  all  the  isolated
S. aureus  strains from diverse clinical samples are presented
in Fig. 1. Distribution of S. aureus in clinical isolates is
presented in Fig. 2. In vitro  susceptibility test in Fig. 1 shows
that, out of the 5 antibiotics tested, cefoxitin worked best on
all S. aureus  isolates including MRSA while clindamycin was
observed to be the least effective.
Molecular characterization of MRSA (S. aureus): The
confirmed MRSA both with Mec A positive and cefoxitin
resistant codes SA 13 and SA 14 were subject to molecular
characterization for genetic confirmation of S. aureus using
standard 16S r RNA standard protocol. Results revealed 97%
identity to reference strain S. aureus subsp. aureus ATCC
35844 (Fig. 3). Accession no D83355 when analyzed by
genome database on ezbiocloud. Accession no given to the
new sequence by gene bank was SUB927972 SA_13
KR336552.
Mec   A   gene   detection   in   multiple   antibiotic   resistant
S. aureus: Out of 500 samples 200 confirmed MRSA were
selected on the basis of antibiotic resistance and analyzed for
Mec A gene detection by PCR. Amplified product of 163 bp
was observed in 104 samples when checked on 1.5% agarose
gel by electrophoresis (Fig. 4).
Sequencing of Mec A gene: The Mec A positive MRSA
confirmed by PCR codes SA_02 and SA_03 were further
processed for gene sequencing by ABI3130 Genetic Analyzer.
The genetic analysis data revealed 100% identity to reference
strain S. aureus  subsp., aureus  MSHR 1132 and M0480 when
blast to genome database on ezbiocloud. All samples were
resistant to drug cefoxitin but only 52% were Mec A gene
positive.
Black seed extract antimicrobial activity assay: Methanolic
extract of N. sativa extract showed excellent anti MRSA
activity, the zone of inhibition was in range of 18-25 mm in
diameter as compare to aqueous extract exhibiting zone of
inhibition in the range of 11-14 mm (Table 1).
Antimicrobial activity of seeds of N. sativa extracts: The
most potent inhibitory effect of N. sativa seed extract was
observed in methanolic extract against MRSA strains with MICs
values in the range of 0.39-1.5 mg mLG1 (p<0.001) and zone of
inhibition of more than 18 mm whereas, aqueous extract
exhibited zone of inhibition in range of 11-14 mm with MICs
in range of 0.22-1.5 mg mLG1 (p<0.001) for clinical S. aureus
strains  (Table 1). Interestingly, 2-4-fold increases in MIC were
found when drug-sensitive clinical strains of S. aureus were
tested, but the MIC/MBC ratio was 0.5 in both cases. The
solvent control (5% DMSO) did not inhibit growth of the
tested bacteria. Our data clearly indicate strong antimicrobial
activity  of  crude  extract  of  seeds  of  N.  sativa  against
Gram-positive   organism,   particularly   methicillin   resistant
S. aureus  and multiple drug resistant S. aureus.
Synergistic activity of plant extracts with antimicrobial
agents: Two different antibiotics (augmentin and cefoxitin)
were  used  for  evaluation  of  synergistic  activity  of  crude
extract and antibiotic. When N. sativa  methanolic extract was
combined with ceftoxitin, it was able to inhibit methicillin
resistant  S.  aureus  and  reduction  in  MICs  was  observed
against S. aureus. In this combination, cefoxitin was able to
inhibit MRSA strains at 0.312 µg mLG1, which was 64 times
lower than the MIC of ceftoxitin alone. When N. sativa seed
extract was combined with augmentin, it was able to inhibit
S. aureus at sub-MIC levels. A significant reduction was also
observed in MICs which explains the strong synergy (FICI 0.37)
in this combination. Synergism was also studied by disc
diffusion method, enlargement in sizes of zone of inhibition
was observed in both the antibiotica and extract combination.
Fig. 1: Antibiotic resistance profiling of MRSA strains isolated from clinical samples
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Table 1: Anti MRSA activity of Nigella sativa seeds extract in different solvent system
Staphylococcus aureus
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
MIC (mg mLG1) MBC (mg mLG1)
--------------------------------------------------------------------------- ----------------------------------------
Aqueous Zone Methanolic Zone Aqueous Methanolic
Clinical samples extract (mm) extract (mm) extract extract R-Type Significant p-value
Blood 0.75±0.03 12.0 0.39±0.03* 25 1.5±0.12 0.50±0.05* MRSA (p-value<0.001)
CSF 0.22±0.12* 11.0 0.39±0.04 25 1.5±0.20 0.50±0.03* MDR (p-value<0.001)
Pus 3.50±0.50 13.0 1.25±0.09* 22 3.3±0.40 1.25±0.12* MSSA (p-value<0.001)
Tissue 0.22±0.05* 12.5 1.25±0.11 21 0.4±0.08* 1.50±0.08 MRSA (p-value<0.001)
Tracheae 0.75±0.22* 12.0 1.50±0.22 18 1.5±0.25* 2.50±0.15 MRSA (p-value<0.001)
Ear discharge 3.70±0.20 14.0 0.78±0.08* 20 3.4±0.30 1.25±0.11* MDR (p-value<0.001)
Reference strain 3.12 13.0 1.50±0.15 18 3.7 1.5 ATCC -
*Statistically significant value (p<0.001), MRSA: Methicillin resistant Staphylococcus aureus, MDR: Multidrug resistant, n: number of isolates, R: Type resistant phenotype,
MIC: Minimal inhibitory concentration, MBC: Minimal bactericidal concentration
Fig. 2: Distribution of Staphylococcus aureus  in clinical isolates
Fig. 3: PCR amplification of 16 S RNA for Staphylococcus
aureus (MRSA)
In general, the zones of inhibition in antibiotic per plant
extract plates were in the range of 05-10 mm wider  than  the
zones of inhibition in the control plates. Result revealed
positive synergism between drug cefoxitin when used with
methanolic extracts of N. sativa  seeds. There was significant
increase of 9 mm in the diameter of zone of inhibition when
cefoxitin and N. sativa used in combination (Fig. 5). Clear zone
for black seed were of sizes 24 mm, augmentin 38 mm and
cefoxitin 16 mm when used alone and increased to 30 mm for
black seed plus cefoxitin and 40 mm augmentin plus black
seeds. In case of paracetamol negative synergism was
observed. Size of zone of inhibition reduced from 11-8 mm
when used in combination with black seeds (Fig. 5).
Combining effects of cefoxitin with tested extracts showed the
inhibition zones 8-9 mm wider.
Phase  contrast  microscopy:  Nigella  sativa   extract  treated
log phase cells of S. aureus  were observed under phase
contrast microscope and time-lapse images were captured.
Two  significant  morphological  changes  were  observed.
When cells of S. aureus  (ATCC33591) were treated with this
compound complete lysis was observed immediately after
treatment. Whereas, when cells of S. aureus  were treated with
sub-lethal concentration of N. sativa  extract, morphology of
treated cells was not similar to that of the bacteria in the
control  culture  and  some  very  large  cells  were  observed
(Fig. 6, 7).
Time kill kinetic assay: Time kill kinetics showed a dose
dependent    bactericidal    effect    on    methicillin-resistant
and    sensitive    S.    aureus    strains,    indicating     strong
anti-Staphylococcal activity of methanolic extract of black
seeds  of  N.  sativa  irrespective  of  the  spectrum  of
resistance  against  other  antimicrobial  agents  (Fig.  8).  The
data clearly indicate strong antimicrobial activity of N.  sativa 
against Gram-positive organisms, particularly Staphylococcus 
species.
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Fig. 4: Mec A gene amplification by PCR with 1 kb DNA ladder
Control: Contained 1 kb DNA ladder, Lane 1-6,8,9 and 11: Mec A positive and were confirmed MRSA,  Lane  7,  8,  11,  13  and  14:  Mec  A  negative  and  MSSA,
Lane 1: Two bands for Mec A, Size of Mec A gene was 163 bp
Fig. 5: Synergism between black seed methanolic extracts with antibiotics (Cefoxitin and augmentin) and non-antibiotics
(Paracetamol)
Fig. 6(a-b): Phase contrast images live cells of S. aureus  (ATCC33591) treated with sub lethal concentration (1/2 MIC) of Nigella
sativa  (a) Control cells without treatment and (b) Cells treated with Nigella sativa
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Fig. 7(a-b): Phase contrast images of live cells of S. aureus. Live cells of S. aureus  treated with MIC concentration of methanolic
extract of Nigella sativa  (a) Control cells without treatment and (b) Cells treated with extract (lysis observed)
Fig. 8: Effect of crude extract of Nigella sativa seeds on
bacterial growth kinetics
DISCUSSION
The   present   study   focused   on   evaluation   of   the
pre-identified potent herbal extract of seeds of N. sativa in
combination with cefoxitin, a third-line antibiotics and
Augmentin a $-lactamase inhibitor, antibiotic against Mec A
gene positive S. aureus.  In  this  study  methanolic  extract  of
N.  sativa  showed good activity against Mec A gene positive
S. aureus  (Fig. 3). There were considerable alternative sources
of natural antimicrobials from plants with different mode of
actions, some of them are employed in traditional medicine
for centuries and was found to have competitive effects
compared to some commercial antibiotics23,39. It was also
reported in a review by Naz40 that N. sativa  extracts were
shown to have outstanding in vitro  antibacterial activity
against Gram positive bacteria40. Other researchers also
reported antibiotic synergism with medicinal plants18,40.
Development of synergistic herbal-synthetic combinations is
a major tool to augment the activity of existing antibiotics
thereby reducing, alleviating or delaying the resistance
process41-46.
Although, the antimicrobial activity of N. sativa plant’s
extract has been previously reported47, but little is known
about their interaction with antimicrobial agents which are
commonly prescribed to treat MDR bacterial infections. Here
the synergistic activity of N. sativa  extract with a wide range
of antimicrobial agents was tested. Nigella sativa showed
synergistic activity with cefoxitin (third line antibiotic) and
amoxicillin against MDR S. aureus  strains. Since N. sativa is
bacteriostatic for Gram positive cocci, so it is hypothesized
that this combination might prevent the recurrence of
bacterial growth caused by antibiotic selective mutants
towards the end of the disease’s course. Therefore, it is
worthwhile to test N. sativa  and its compounds for synergistic
activity with third line antibiotics in vivo.
It was very surprising to see that N. sativa was able to
reverse  augmentin  resistance  in   MRSA.   Augmentin   is   a
$-lactam antibiotic that inhibits cell wall peptidoglycan
through binding and competitive inhibition of Penicillin
Binding Proteins (PBPs)12. Activation of Mec A gene and gene
variants  led  to  the  formation  of  PBP2a,  which  binds  with
$-lactam   antibiotics   in   lower   affinity,   resulting    in    drug
965
 
 
 
(a)                                                                                                      (b) 
Int. J. Pharmacol., 13 (8): 958-968, 2017
resistance11,12. Therefore, unavailability of PBP2a might resume
antimicrobial action of oxacillin in MRSA strains. Already it has
been shown that N. sativa alone induces ultrastructure
changes in MRSA, indicating significant changes in the
molecular machinery of bacterial cells. It is speculated that the
addition of N. sativa might interfere in the synthesis or
transportation  of  PBP2a  levels  on  the  cell  membrane.
Previous studies also showed similar effects on oxacillin
resistance by different compounds such as phenothiazine,
chlorpromazine, thioridazine, inducing physiological damage
to bacterial cell membranes48,49. Further studies are warranted
to understand the exact mechanism of action. This study is the
first to report the synergistic antimicrobial effects of N. sativa
in combination with $-lactam antibiotics. In a separate study,
these extracts were tested for toxic effects on human RBCs.
Nigella sativa extract was found to be non-toxic on the
concentrations tested for antimicrobial activity. The synergistic
antimicrobial  effects  of  crude  methanolic  extract  in
combination with $-lactam antibiotics provided the evidence
to advance the study by separating, purifying and analyzing
the different bioactive components present in crude extract of
N. sativa. Then structural characterization of the compounds
that are responsible for anti-MRSA activity should be carried
out by using cutting edge technologies.
CONCLUSION
On the basis of results of antibacterial assay of this study
S. aureus  was found to be more sensitive to methanolic
extract of N. sativa  as compared to aqueous extract. It was
also concluded that black seeds extract worked well in
combination   with   augmentin   and   cefoxitin   while   the
anti-MRSA activity is reduced when black seeds extract was
used in combination with a non-antibiotic paracetamol.
SIGNIFICANCE STATEMENTS
Development   of   synergistic   herbal-synthetic
combinations is a major tool to augment the activity of
existing antibiotics thereby reducing, alleviating or delaying
the  resistance  process.   Ethnobotanical  studies  showed  it
is a medicinal plant which is essential in the treatment of
microbial infections. Data obtained in the study clearly
indicated strong antimicrobial activity of methanolic crude
extract of seeds of N. sativa  against Gram-positive organism,
particularly methicillin resistant S. aureus  and multiple drug
resistant S. aureus. This study is the first to report the
synergistic antimicrobial effects of N. sativa in combination
with $-lactam antibiotics.
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